GLP-1 Drugs Explained: Mechanism, Muscle Loss, and Weight Rebound Risk

GLP-1 receptor agonists (semaglutide, liraglutide, and related drugs) are the most impactful weight-loss medications developed in decades. The STEP trials showed 15%+ average weight loss over 68 weeks with 2.4mg semaglutide — results previously achievable only through bariatric surgery. But three underappreciated issues deserve serious attention before starting treatment: muscle loss, weight regain after stopping, and the implications of long-term use.

How GLP-1 drugs work: appetite suppression and beyond

GLP-1 (glucagon-like peptide-1) is naturally secreted by intestinal L-cells after meals, but is degraded within 2 minutes by DPP-4 enzymes. Pharmaceutical GLP-1 agonists are structurally modified to extend action to hours (liraglutide) or a week (semaglutide). Their mechanisms include: hypothalamic appetite suppression (continuous, not meal-triggered); delayed gastric emptying (extending satiety); glucose-dependent insulin stimulation (low hypoglycemia risk); and glucagon suppression (reducing hepatic glucose output). The result is a substantial, sustained reduction in food intake — without requiring conscious restriction.

Muscle loss: the most underappreciated risk

STEP trial data and real-world studies show that 30–40% of weight lost on GLP-1 drugs is lean mass — far above the ideal threshold of below 20%. The mechanism is straightforward: aggressive appetite suppression leads to inadequate total food intake, particularly insufficient protein. The body responds to caloric deficit by catabolizing muscle for energy.

Muscle loss has cascading consequences: lower basal metabolic rate (making post-drug weight regain faster), increased sarcopenia risk (particularly dangerous in older adults), and reduced functional capacity. Ensuring protein intake of at least 1.2g per kilogram of body weight throughout GLP-1 treatment is now considered standard best practice by metabolic medicine specialists.

The weight regain problem: what happens when you stop

The STEP 4 extension trial followed participants one year after semaglutide discontinuation. Average weight regain: two-thirds of lost weight within 12 months. This is not surprising — GLP-1 drugs suppress appetite signals but do not address the underlying metabolic environment (insulin resistance, dietary patterns, fat distribution) that produced the weight gain. Remove the suppression, and the biology reasserts itself.

This creates a difficult reality: for many patients, GLP-1 drugs may need to be taken indefinitely to maintain results. The long-term cost, side effect profile, and unknown 20+ year effects of chronic use are all factors that require frank discussion with prescribing physicians.

Side effects and appropriate candidates

The most common side effects are gastrointestinal: nausea (30–40%), vomiting, diarrhea, and constipation — most prominent during dose escalation. Less common but serious risks include pancreatitis and gallstone formation (from rapid weight loss). Thyroid C-cell tumors observed in rodents have not been confirmed in humans, but people with personal or family history of thyroid cancer are typically advised to avoid these drugs. In Taiwan, GLP-1 agonists are available by prescription for BMI ≥ 30, or BMI ≥ 27 with obesity-related comorbidities, and are self-pay (approximately NT$5,000–12,000/month).

For personalized dietary guidance on metabolic health, visit cnfcd.life or reach out for an initial consultation.

— Hsien-Hung Shih | ResetWith Health Coach | cnfcd.life

📚 科學觀點與參考來源

1. Westerterp-Plantenga MS, et al. Dietary protein, metabolism, and body-weight regulation. J Nutr. 2009. PubMed →
2. Morton RW, et al. A systematic review of protein supplementation and resistance training. Br J Sports Med. 2018. PubMed →

本文涉及的科學觀點僅供參考，不構成醫療建議。如有相關健康問題，請諮詢合格醫療專業人員。